| NCT ID | NCT06038630 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Bastiaan Driehuys |
| Condition | Interstitial Lung Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2024-01-12 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 125 participants in total. It began in 2024-01-12 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Eligibility Criteria
Inclusion Criteria for Healthy Volunteers: (Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial) 1. Outpatients of either gender, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol (Consent must be given before any study procedures are performed.) 3. Subject has no diagnosed pulmonary conditions 4. Subject has not smoked in the previous 5 years 5. Smoking history, if any, is less than or equal to 5 pack-years 6. No history of using other inhaled products more than 1/week for \> 1 year Inclusion Criteria for Transfusion and Phlebotomy Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following: 1. Patients who are scheduled to receive a red cell transfusion for anemia. 2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia 3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above) Inclusion Criteria for Oxygen Administration Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following categories (ILD, Dyspnea, CTEPH, or Healthy): 1. Interstitial Lung Disease or Dyspnea * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea OR 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) * Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans OR 3. Healthy Volunteer (criteria noted above) Inclusion Criteria for Acute or Chronic Pulmonary Embolism Patients: 1. In-patient or outpatients of either sex, age \> 18 2. Willing and able to give informed consent and adhere to visit/protocol And one of the following categories (Acute or Chronic) 1. Acute Pulmonary Embolism * Patients presenting with acute PE 24-48hrs post-admission * Willing to return after 3-6 months of anti-coagulation therapy OR 2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) * Patients with a diagnosis of CTEPH, defined as mean PA pressure \>20 mmHg with a pulmonary vascular resistance \>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans Exclusion Criteria for All subjects: Subjects presenting with any of the following will not be included in the trial: 1. MRI is contraindicated based on responses to MRI screening questionnaire 2. Subject is pregnant or lactating 3. Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal canula 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 5. Subject has history of any known ventricular cardiac arrhythmia 6. Subject has history of cardiac arrest within the last year 7. Subject does not fit into 129Xe vest coil used for MRI 8. Subject cannot hold his/her breath for 10 seconds 9. Subject deemed unlikely to be able to comply with instructions during imaging 10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Contact & Investigator
Joseph Mammarappallil, MD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT06038630 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06038630 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06038630 currently recruiting?
Yes, NCT06038630 is actively recruiting participants. Contact the research team at bastiaan.driehuys@duke.edu for enrollment information.
Where is the NCT06038630 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT06038630 clinical trial?
NCT06038630 is sponsored by Bastiaan Driehuys. The principal investigator is Joseph Mammarappallil, MD at Duke University. The trial plans to enroll 125 participants.